| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G | 2024-03-15 | TCG Crossover GP II, LLC | NEKTAR THERAPEUTICS | 20,046,350 | 9.9% | EDGAR |
| SC 13G/A | 2024-02-14 | CITADEL ADVISORS LLC | NEKTAR THERAPEUTICS | - | 3.0% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | NEKTAR THERAPEUTICS | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | Deep Track Capital, LP | NEKTAR THERAPEUTICS | 18,400,000 | 9.6% | EDGAR |
| SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | NEKTAR THERAPEUTICS | 12,042,873 | 6.3% | EDGAR |
| SC 13G | 2023-08-17 | RA CAPITAL MANAGEMENT, L.P. | NEKTAR THERAPEUTICS | 18,700,000 | 9.8% | EDGAR |
| SC 13G/A | 2023-07-10 | Invesco Ltd. | NEKTAR THERAPEUTICS | 5,535,430 | 2.9% | EDGAR |
| SC 13G/A | 2023-07-10 | VANGUARD GROUP INC | NEKTAR THERAPEUTICS | 12,056,187 | 6.4% | EDGAR |
| SC 13G/A | 2023-07-07 | PRIMECAP MANAGEMENT CO/CA/ | NEKTAR THERAPEUTICS | 8,149,876 | 4.3% | EDGAR |
| SC 13G/A | 2023-07-07 | BlackRock Inc. | NEKTAR THERAPEUTICS | 8,604,322 | 4.5% | EDGAR |
| SC 13G | 2023-07-03 | CITADEL ADVISORS LLC | NEKTAR THERAPEUTICS | - | 4.0% | EDGAR |
| SC 13G/A | 2023-05-05 | BlackRock Inc. | NEKTAR THERAPEUTICS | 18,300,674 | 9.7% | EDGAR |
| SC 13G | 2023-04-14 | Deep Track Capital, LP | NEKTAR THERAPEUTICS | 12,302,237 | 6.5% | EDGAR |
| SC 13G/A | 2023-02-09 | PRIMECAP MANAGEMENT CO/CA/ | NEKTAR THERAPEUTICS | 15,659,053 | 8.3% | EDGAR |
| SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | NEKTAR THERAPEUTICS | 23,065,775 | 12.3% | EDGAR |
| SC 13G/A | 2023-02-06 | WELLINGTON MANAGEMENT GROUP LLP | NEKTAR THERAPEUTICS | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-02-02 | Invesco Ltd. | NEKTAR THERAPEUTICS | 37,327,473 | 19.9% | EDGAR |
| SC 13G/A | 2023-01-23 | BlackRock Inc. | NEKTAR THERAPEUTICS | 35,928,093 | 19.1% | EDGAR |
| SC 13G/A | 2022-02-11 | Invesco Ltd. | NEKTAR THERAPEUTICS | 36,891,494 | 20.0% | EDGAR |
| SC 13G/A | 2022-02-10 | PRIMECAP MANAGEMENT CO/CA/ | NEKTAR THERAPEUTICS | 17,412,422 | 9.4% | EDGAR |